Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Neuromyelitis Optica (Devic’s Syndrome) Overview 8 Therapeutics Development 9 Pipeline Products for Neuromyelitis Optica (Devic’s Syndrome) - Overview 9 Pipeline Products for Neuromyelitis Optica (Devic’s Syndrome) - Comparative Analysis 10 Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics under Development by Companies 11 Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics under Investigation by Universities/Institutes 12 Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Neuromyelitis Optica (Devic’s Syndrome) - Products under Development by Companies 16 Neuromyelitis Optica (Devic’s Syndrome) - Products under Investigation by Universities/Institutes 17 Neuromyelitis Optica (Devic’s Syndrome) - Companies Involved in Therapeutics Development 18 Acorda Therapeutics, Inc. 18 Alexion Pharmaceuticals, Inc. 19 Bionure Farma, S.L. 20 Chugai Pharmaceutical Co., Ltd. 21 Clene Nanomedicine, Inc. 22 HanAll Biopharma Co., Ltd. 23 Karus Therapeutics Limited 24 Marathon Pharmaceuticals, LLC 25 MedImmune, LLC 26 Opexa Therapeutics, Inc. 27 Shire Plc 28 Takeda Pharmaceutical Company Limited 29 Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Target 31 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 ANV-201 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 BN-201 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 C1 esterase inhibitor (human) - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Cellular Immunotherapy for Central Nervous System Disorders - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 CNMAU-8 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 D-15107 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 dalfampridine ER - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 eculizumab - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 HL-161 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 immune globulin (human) - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 inebilizumab - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 KA-1463 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 OPX-212 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 SA-237 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Small Molecule for Neuromyelitis Optica - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Neuromyelitis Optica (Devic’s Syndrome) - Recent Pipeline Updates 64 Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects 78 Neuromyelitis Optica (Devic’s Syndrome) - Product Development Milestones 79 Featured News & Press Releases 79 Nov 24, 2015: MS Trial Alert: Investigators Recruiting People with Relapsing NMOSD for Study of an Investigational Medicine (Eculizumab) 79 Nov 10, 2015: Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica Program 79 Sep 29, 2015: FDA Approval To Commence Phase I Single Ascending Dose Protocol 80 May 08, 2015: Initiation Of Phase I Clinical Program 80 Apr 20, 2015: Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology 2015 Annual Meeting 80 Apr 15, 2015: Clene Receives IMPD Approval; Phase I Clinical Program Planned 81 Nov 25, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica 81 Sep 08, 2014: Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program 82 Aug 27, 2014: Clene Files Investigational New Drug Application With FDA 82 Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis 83 Appendix 85 Methodology 85 Coverage 85 Secondary Research 85 Primary Research 85 Expert Panel Validation 85 Contact Us 85 Disclaimer 86

List of Tables Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H1 2016 9 Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome) - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Acorda Therapeutics, Inc., H1 2016 18 Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Alexion Pharmaceuticals, Inc., H1 2016 19 Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Bionure Farma, S.L., H1 2016 20 Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016 21 Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Clene Nanomedicine, Inc., H1 2016 22 Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 23 Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Karus Therapeutics Limited, H1 2016 24 Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Marathon Pharmaceuticals, LLC, H1 2016 25 Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by MedImmune, LLC, H1 2016 26 Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Opexa Therapeutics, Inc., H1 2016 27 Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Shire Plc, H1 2016 28 Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 29 Assessment by Monotherapy Products, H1 2016 30 Number of Products by Stage and Target, H1 2016 32 Number of Products by Stage and Mechanism of Action, H1 2016 34 Number of Products by Stage and Route of Administration, H1 2016 36 Number of Products by Stage and Molecule Type, H1 2016 38 Neuromyelitis Optica (Devic’s Syndrome) Therapeutics - Recent Pipeline Updates, H1 2016 64 Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects, H1 2016 78 List of Figures Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H1 2016 9 Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome) - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Products, H1 2016 15 Assessment by Monotherapy Products, H1 2016 30 Number of Products by Top 10 Targets, H1 2016 31 Number of Products by Stage and Top 10 Targets, H1 2016 31 Number of Products by Top 10 Mechanism of Actions, H1 2016 33 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 33 Number of Products by Routes of Administration, H1 2016 35 Number of Products by Stage and Routes of Administration, H1 2016 35 Number of Products by Molecule Types, H1 2016 37 Number of Products by Stage and Molecule Types, H1 2016 37

Acorda Therapeutics, Inc. Alexion Pharmaceuticals, Inc. Bionure Farma, S.L. Chugai Pharmaceutical Co., Ltd. Clene Nanomedicine, Inc. HanAll Biopharma Co., Ltd. Karus Therapeutics Limited Marathon Pharmaceuticals, LLC MedImmune, LLC Opexa Therapeutics, Inc. Shire Plc Takeda Pharmaceutical Company Limited